

Edgar Filing: NOVEN PHARMACEUTICALS INC - Form SC 13G

NOVEN PHARMACEUTICALS INC
Form SC 13G
February 11, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.)*

Noven Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

670009109
(CUSIP Number)

December 31, 2003
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO: 670009109

-
- 1. Names of Reporting Persons. Palisade Capital Management, L.L.C.
I.R.S. Identification Nos. Of Above Persons (entities only): 22-3330049

 - 2. Check the Appropriate Box if a Member of a Group (See Instructions) N/A
(a) _____ (b) _____

 - 3. SEC Use Only

 - 4. Citizenship or Place of Organization:

Edgar Filing: NOVEN PHARMACEUTICALS INC - Form SC 13G

New Jersey	
	5. Sole Voting Power
Number of Shares Beneficially Owned by Each Reporting Person With:	1,253,200*
	6. Shared Voting Power
	N/A
	7. Sole Dispositive Power
	1,253,200*
	8. Shared Dispositive Power
	N/A
9. Aggregate Amount Beneficially Owned by Each Reporting Person:	1,253,200*
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):	N/A
11. Percent of Class Represented by Amount in Row (9):	5.56%
12. Type of Reporting Person (See Instructions):	IA

*The shares of the Issuer beneficially owned by the reporting person are held on behalf of the reporting person's client in an account over which the reporting person has complete investment discretion. No other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such shares.

-2-

Item 1.

(a) Name Of Issuer:

Noven Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

11960 S.W. 144th Street,
Miami, FL 33186.

Item 2.

(a) Name of Person Filing:

Edgar Filing: NOVEN PHARMACEUTICALS INC - Form SC 13G

Palisade Capital Management, L.L.C.

(b) Address of Principal Business Office or, if none, Residence:

One Bridge Plaza, Suite 695,
Fort Lee, NJ 07024

(c) Citizenship:

New Jersey

(d) Title of Class of Securities:

Common Stock

(e) CUSIP Number:

670009109

Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

-3-

- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

(a) Amount beneficially owned:

1,253,200

(b) Percent of Class:

Edgar Filing: NOVEN PHARMACEUTICALS INC - Form SC 13G

5.56%

- (c) Number of shares as to which the person has:
- | | |
|--|-----------|
| (i) Sole power to vote or to direct the vote | 1,253,200 |
| (ii) Shared power to vote or to direct the vote | N/A |
| (iii) Sole power to dispose or to direct the disposition of | 1,253,200 |
| (iv) Shared power to dispose or to direct the disposition of | N/A |

Item 5. Ownership of Five Percent or Less of a Class.

N/A

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

The shares of the Issuer beneficially owned by the reporting persons are held on behalf of the reporting persons' clients in accounts over which the reporting persons have complete investment discretion. No other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such shares. No client account contains more than five percent of the class.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

N/A

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

-4-

Item 10. Certification.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 9, 2004

Date

Edgar Filing: NOVEN PHARMACEUTICALS INC - Form SC 13G

Palisade Capital Management, LLC

/s/ Steven E. Berman

Steven E. Berman, Member

Attention: Intentional misstatements or omissions of fact constitute Federal
criminal violations (See 18 U.S.C. 1001)

-5-